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Abstract
Acute promyelocytic leukemia (APL) is epitomized by the chromo-
somal translocation t(15;17) and the resulting oncogenic fusion
protein PML-RARa. Although acting primarily as a transcriptional
repressor, PML-RARa can also exert functions of transcriptional
co-activation. Here, we find that PML-RARa stimulates transcrip-
tion driven by HIF factors, which are critical regulators of adaptive
responses to hypoxia and stem cell maintenance. Consistently,
HIF-related gene signatures are upregulated in leukemic promyel-
ocytes from APL patients compared to normal promyelocytes.
Through in vitro and in vivo studies, we find that PML-RARa
exploits a number of HIF-1a-regulated pro-leukemogenic func-
tions that include cell migration, bone marrow (BM) neo-angio-
genesis and self-renewal of APL blasts. Furthermore, HIF-1a levels
increase upon treatment of APL cells with all-trans retinoic acid
(ATRA). As a consequence, inhibiting HIF-1a in APL mouse models
delays leukemia progression and exquisitely synergizes with ATRA
to eliminate leukemia-initiating cells (LICs).
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Introduction
Acute promyelocytic leukemia (APL) is a sub-type of acute myeloid
leukemia (AML) distinguished by a differentiation block at the prom-
yelocytic stage and the largely predominant t(15;17) chromosomal
translocation generating the PML-RARa fusion protein (Ablain & de The,
2011). PML-RARaactsmainlyasatranscriptionalrepressor, by blocking
expression of a number of genes involved in myeloid differentiation
through relaxed DNA-binding capacity and recruitment of transcrip-
tional co-repressors and chromatin modifiers (Ablain & de The, 2011).
Nonetheless, PML-RARa also exerts functions of transcriptional co-
activation toward transcription factors like AP-1 and GATA-2 (Dou-
cas et al, 1993; Tsuzuki et al, 2000), and induces expression of genes
promoting stem cells maintenance (Viale et al, 2009). Moreover,
treatment of APL cells with therapeutic doses of all-trans retinoic acid
(ATRA) induces transcriptional activation by PML-RARa, followed
by PML-RARa degradation and rapid and effective APL blast
differentiation and leukemia de-bulking (Ablain & de The, 2011).
Hypoxia-inducible transcription factors (HIFs) are often upregu-
lated in solid tumors and foster tumorigenesis in several ways,
which include cell migration, neo-angiogenesis and maintenance of
cancer stem cells (Lu & Kang, 2010; Lee & Simon, 2012). In
lymphoma and AML, HIF-1a was recently found upregulated specifi-
cally in LICs, where it was shown to stimulate self-renewal (Lee &
Simon, 2012). Using a combination of in vitro and in vivo studies
and in silico analysis of patients’ gene expression profiles, we show
that in APL, PML-RARa functionally cooperates with HIF factors,
particularly HIF-1a, and exploits the transcriptional repertoire of
HIF-1a to promote not only LICs maintenance but also leukemia
progression at multiple levels.
Results
PML-RARa is a HIF-a transcriptional co-activator
We have previously reported that PML inhibits HIF-1a-mediated
transcription (Bernardi et al, 2006). Because PML-RARa is a
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whether PML-RARa activated HIF-1a through PML inhibition.
Transcription assays showed that PML-RARa activated transcription
by HIF-1a and HIF-2a in a dose-dependent manner (Fig 1A),
although both PML and RARa inhibited HIF-1a-mediated transcrip-
tion (Fig 1B). However, HIF-1a activation by PML-RARa did not
depend on PML inhibition as it also occurred in Pml
/ mouse
embryonic fibroblasts (MEFs), regardless of higher basal HIF-1a
activity (Bernardi et al, 2006) (Fig 1C). Also, increased HIF activity
was not caused by protein accumulation (Supplementary Fig S1A
and B) and was not further stimulated by ATRA treatment (Supple-
mentary Fig S1C), in contrast to PML-RARa-mediated activation of
AP-1 and GATA-2 (Doucas et al, 1993; Tsuzuki et al,2 0 0 0 ) .I n t e r e s t -
ingly, other APL fusion proteins PLZF-RARa and NPM-RARa also
activated transcription by HIF-1a upon stabilization by the hypoxia-
mimetic agent cobalt chloride (CoCl2, which at the conditions used
in our assays induced HIF-1a and not HIF-2a transcriptional activity,
Supplementary Fig S1D and E), while fusion proteins of other AML
sub-types such as AML1-ETO did not (Fig 1D). These data suggest
that activation of HIF factors may be a common event in APL.
To assess whether the functional cooperation of PML-RARa and
HIF-1a is mediated by physical interaction, co-immunoprecipitation
experiments were performed in HEK-293 and NB4 cells. Overexpres-
sed stable forms of HIF-1a and HIF-2a as well as endogenous HIF-1a
were co-immunoprecipitated with PML-RARa and with PML (Fig 1E
and F); however, they did not directly interact in vitro (Supplemen-
tary Fig S1F and G).
Taken together, these data indicate that PML-RARa functionally
cooperates with HIF factors independently of PML inhibition, HIF-a
accumulation, ATRA binding and direct interaction. The molecular
mechanisms driving PML-RARa-HIF cooperation remain to be eluci-
dated, but may involve indirect interactions within larger protein
complexes. Also, these interactions could be mediated by both
moieties of PML-RARa, because both PML and RARa interfere with
HIF-mediated transcription, PML interacts with HIF-a, and different
RARa fusion proteins activate HIF-1a. This suggests that PML-RARa
may hijack physiological functions of PML and RARa toward a new
functional interaction with HIF-1a.
HIF-regulated gene signatures are upregulated in human APL
To understand whether the functional cooperation of PML-RARa
with HIF-1a is relevant to APL pathogenesis, expression of hypoxia-
regulated gene signatures was evaluated in microarray data of
normal and leukemic promyelocytes from APL patients (Marstrand
et al, 2010). A number of HIF-related gene signatures were found
significantly correlated with the distinction between leukemic
promyelocytes and normal human promyelocytes (Fig 2A). To gain
a better understanding of the direct role of HIF-1a in human APL, a
list of bona fide HIF-1a target genes was constructed based on
current literature (Wenger et al, 2005) by selecting HIF-1a targets
validated in multiple experimental settings and provided with func-
tional HIF-1a binding sites (Supplementary Table S1). Enrichment
analysis revealed that genes belonging to this signature were signifi-
cantly enriched in the genes upregulated in APL vs normal promyel-
ocytes (Fig 2B), thus confirming that direct transcriptional targets of
HIF-1a are upregulated in APL and that activation of HIF-regulated
signatures is relevant for human APL.
HIF-1a inhibition impairs APL cell migration, neo-angiogenesis
and self-renewal
To study the functions of endogenous HIF factors in APL, HIF-1a
and HIF-2a expressions were analyzed in APL NB4 cells. HIF-1a
mRNA was significantly expressed, similarly to VEGF, which is
highly expressed in APL patients (Gutierrez et al, 2005), while
HIF-2a levels were very low (Fig 3A). Consistently, HIF-1a was
detected by Western blotting upon CoCl2 treatment but also in
normoxic conditions (Fig 3B). The mechanisms leading to normoxic
HIF-1a expression in NB4 cells are unknown, but may not depend
on PML-RARa as PML-RARa overexpression did not modulate
HIF-1a protein (Supplementary Fig S1A and B). Because it was
recently reported that HIF-1a is regulated in an oxygen-independent
manner in hematopoietic stem cells (Nombela-Arrieta et al, 2013), it
is possible that in some hematopoietic cells oxygen-sensing mecha-
nisms are tuned down to allow basal expression of HIF factors.
Chronic HIF-1a down-regulation by shRNA led to specific inhibi-
tion of HIF-1a and down-regulation of bona fide HIF target genes in
NB4 cells (Fig 3B and C and Supplementary Fig S2A). To under-
stand the role of HIF-1a in APL, we analyzed a number of known
HIF-regulated functions: in NB4 cells, HIF-1a down-regulation did
not affect proliferation (Supplementary Fig S2B), but impaired basal
cell migration (Fig 3D) and in vivo BM homing (Fig 3E), consis-
tently with CXCR4 down-regulation (Fig 3C). Conversely, in vitro
migration toward SDF-1 or VEGF did not occur (Supplementary Fig
S2C) due to receptor internalization in culture (Tavor et al, 2004).
Next, as APL patients have increased BM neo-angiogenesis and high
VEGF levels (Kini et al, 2001), and VEGF expression in regulated by
HIF-1a in NB4 (Fig 3C), microvessel density was analyzed in vivo.
HIF-1a down-regulation significantly inhibited neo-angiogenesis
both in BM (Fig 3F) as well as in other tumor masses (Supplemen-
tary Fig S2D). Also, HIF-1a down-regulation significantly increased
the survival of immunocompromised mice (Fig 3G).
Finally, as it was recently reported that HIF-1a regulates mainte-
nance of LICs (Wang et al, 2011), we analyzed the effect of HIF-1a
inhibition on leukemia self-renewal in vitro. Methylcellulose
re-plating assays showed that NB4 CFU-L (colony-forming unit
leukemia) increased upon serial re-plating (Lin et al, 2010) only in
cells expressing HIF-1a (Fig 3H), thus indicating that self-renewal of
CFU-L requires HIF-1a. Also, NB4 colonies appeared more compact
upon HIF-1a silencing, consistently with decreased cell migration
(Fig 3H).
Inhibition of HIF-1a with an unrelated shRNA confirmed the
impairment in cell migration and CFU-L re-plating efficacy and
prolonged mice survival in xenograft experiments (Supplementary
Fig S3A–E). Unexpectedly, stable silencing of HIF-2a also impaired
NB4 CFU-L re-plating efficacy and slightly prolonged mice survival,
although not affecting cell migration (Supplementary Fig S3B–E).
This occurred despite the low expression of HIF-2a in NB4 cells,
which was also observed in APL patients (Fig 3A and Supplemen-
tary Fig S3F). Interestingly, it was recently shown that HIF-2a
promotes maintenance of human CD34
+ hematopoietic stem cells
(Rouault-Pierre et al, 2013), although we found that also in this
context HIF-2a is expressed at lower levels than HIF-1a (Supplemen-
tary Fig S3G). Therefore, it appears that HIF-2a exerts critical func-
tions in normal and transformed hematopoietic cells regardless of
its expression levels.
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641Based on the results obtained upon HIF-1a chronic silencing, we
next wished to test the consequences of acute HIF-1a inhibition.
The RNA antagonist EZN-2968 is a locked nucleic acid-modified
oligonucleotide (LNA-ON) specifically targeting HIF-1a, while EZN-
3088 is a control LNA-ON (Greenberger et al, 2008). Strong inhibi-
tion of HIF-1a by EZN-2968 (Fig 3I) recapitulated more efficiently
what was previously observed by chronic HIF-1a silencing: block-
ade of cell migration and CFU-L efficacy upon re-plating (Fig 3J and
K), as well as delayed leukemia progression (Fig 3L).
Finally, to substantiate our experiments in another APL cell
context, we took advantage of the U937-PR9 cell line where PML-
RARa is expressed under the control of a zinc (Zn)-inducible
AB
C
E
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Figure 1. PML-RARa is a HIF-a transcriptional co-activator.
HIF-a transactivation assays (A–D) with HRE-luciferase construct. Results are presented as Luciferase/Renilla ratio (mean  s.e.m. of experiments performed in triplicate).
A HEK-293 cells transfected with stable mutants of HIF-1a or HIF-2a and increasing concentrations of PML-RARa.
B HEK-293 cells transfected with a stable form of HIF-1a along with PML-RARa, PML or RARa.
C Wild-type and Pml
/ MEFs transfected with HIF-1a and PML-RARa. Asterisks indicate fold change induction of HIF-1a-mediated transactivation upon PML-RARa
expression.
D HEK-293 cells transfected with the indicated fusion genes and treated with CoCl2.
E Co-immunoprecipitation of exogenous stable forms of HIF-1a (left panel) and HIF-2a (right panel) and PML-RARa with a PML-directed antibody in HEK-293 cells. Of
note, exogenously expressed PML-RARa migrates very closely to endogenous PML.
F Co-immunoprecipitation of endogenous HIF-1a and PML-RARa with a PML-directed antibody in NB4 cells treated with CoCl2.
Data information: All experiments were repeated at least twice.
Source data are available for this figure.
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642promoter (Grignani et al, 1998). Interestingly, acute induction of
PML-RARa with Zn increased HIF-1a, GLUT1 and CXCR4 mRNA
levels, while having no significant effect on U937-MT control cells
(Supplementary Fig S4A and B). Strong inhibition of HIF-1a in
U937-PR9 cells impaired cell migration and colony formation more
efficiently when PML-RARa was expressed, albeit also affecting
migration and clonogenicity in the absence of PML-RARa (Supple-
mentary Fig S4C–E). These data indicate that HIF-1a may play a role
also in leukemic contexts different from APL, but forced expression
of PML-RARa further sensitizes leukemic cells to its inhibition.
Taken together, our data indicate that hampering HIF-1a func-
tions affects different aspects of APL biology that include cell migra-
tion and self-renewal, thus resulting in delayed leukemia
progression.
HIF-1a inhibition synergizes with ATRA treatment to
eradicate APL
It has long been known that ATRA treatment promotes rapid APL
blast differentiation but is not sufficient to eradicate LICs and rarely
leads to prolonged disease remission (Sanz et al, 2008; Lo-Coco
et al, 2010). Additionally, in vitro studies suggest that ATRA may
promote the expansion of APL LICs (Zheng et al, 2007). Interest-
ingly, we found that ATRA treatment induced HIF-1a expression
(Fig 4A) and increased clonogenicity in a HIF-1a-dependent manner
in NB4 cells (Fig 4B).
To understand whether HIF-1a inhibition led to LICs elimination
especially upon ATRA treatment, we turned to a mouse APL model
(Minucci et al, 2002). Lineage-negative BM cells were transduced
NAME SIZE ES NES NOM p-val FDR q-val
BIOCARTA_HIF_PATHWAY 14 0.7580255 1.884483 0 0
HARRIS_HYPOXIA 77 0.6934518 1.7193973 0 0.001311905
LEONARD_HYPOXIA 39 0.7846712 1.5757978 0.005908419 0.021862118
SEMENZA_HIF1_TARGETS 33 0.6500427 1.5379621 0.025232404 0.02771388
PID_HIF1_TFPATHWAY 60 0.62517524 1.5148182 0.011034483 0.03886971
JIANG_HYPOXIA_NORMAL 255 0.46614113 1.47441 0.013081395 0.056857403
WINTER_HYPOXIA_METAGENE 212 0.53121847 1.4629508 0.002386635 0.056912452
WINTER_HYPOXIA_UP 67 0.50628483 1.4586831 0.023977432 0.05435155
ELVIDGE_HYPOXIA_UP 148 0.5535147 1.4412668 0.003614458 0.061094847
ELVIDGE_HYPOXIA_BY_DMOG_UP 114 0.55980015 1.4260447 0.00617284 0.06724023
MANALO_HYPOXIA_UP 188 0.49226585 1.3800579 0.042183623 0.096533485
KIM_HYPOXIA 22 0.6424534 1.3786607 0.042288557 0.091070436
MIZUKAMI_HYPOXIA_DN 5 0.8918009 1.3461848 0.023183925 0.111282125
A
B
SIZE:111
NES: 1.5486059
NOM p-val: 0.0174966
FDR q-val: 0.028552
Figure 2. HIF-1a-dependent gene signatures are overexpressed in human APL promyelocytes compared to normal promyelocytes.
A MSigDb signatures related to hypoxia and HIF-1a pathways enriched in the comparison between APL and normal promyelocytes gene expression. Enrichment scores
(ES) and normalized ES (NES) accounting for the gene set size are reported. Significance was estimated in terms of nominal P-value and FDR Q-value.
B GSEA plot for the comparison between APL and normal promyelocytes (PM) gene expression showing significant enrichment of HIF-1a direct targets in the APL-
upregulated genes.
ª 2014 The Authors EMBO Molecular Medicine Vol 6 |N o5 | 2014
Nadia Coltella et al PML-RARa exploits HIF-1a for APL pathogenesis EMBO Molecular Medicine
643with PML-RARa followed by transplantation into lethally irradiated
syngeneic mice. Transplanted mice developed a fatal myeloid leuke-
mia that recapitulates human APL with peripheral leukocytosis,
colonization of the BM and spleen and responsiveness to ATRA
(Minucci et al, 2002; Fig 4). We first aimed at confirming the effects
of HIF-1a inhibition in mouse APL. Ex vivo APL blasts electropora-
tion with EZN-2968 led to significant impairment in the expression
of HIF-1a and HIF-target genes (Fig 4C) and inhibited basal and
SDF-1-directed cell migration, CFU-L formation and leukemia
involvement in peripheral blood (Fig 4D-F), leading to increased
mice survival (Fig 4G).
To next assess whether HIF-1a inhibition cooperated with ATRA
to eliminate LICs in vivo, APL cells were transfected with EZN-2968
or EZN-3088 and transplanted into syngeneic mice. Leukemic mice
were treated with ATRA for 4 days, after which BM was trans-
planted into recipient mice to measure leukemia engraftment by
LICs. Strikingly, while short ATRA treatment or HIF-1a silencing
only modestly affected the survival of transplanted animals,
combined treatment exquisitely synergized in preventing leukemia
engraftment (Fig 4H). Moreover, HIF-1a inhibition also synergized
with ATRA in promoting leukemia de-bulking (Fig 4I), therefore
suggesting that a strong inhibition of HIF-1a may cooperate with
ATRA not only to blunt the leukemia-initiating capacity of APL cells,
but also their in vivo survival and/or differentiation.
Discussion
PML-RARa is a gain of function transcription factor that is believed
to exert leukemogenic functions mostly by acting as a transcrip-
tional repressor. Here, we define a new pro-leukemogenic axis
exploited by PML-RARa through its synergistic cooperation with
HIF transcription factors. We find that despite both PML and RARa
inhibit HIF-1a-mediated transcription, the fusion protein PML-
RARa acts as a HIF-a transcriptional co-activator. Accordingly,
HIF-dependent signatures are upregulated in leukemic blasts of
APL patients, and binding sites for the HIF-a heterodimerization
partner HIF-1b are enriched in the promoters of genes preferen-
tially expressed in APL blasts (Marstrand et al, 2010), thus indicat-
ing that activation of HIF factors is relevant to the pathophysiology
of APL.
Our findings challenge the current view that PML-RARa exerts
oncogenic functions by transcriptional repression, while switching
to a transcriptional activator upon ATRA treatment, and indicate
that important functions of PML-RARa may also be mediated by
transcriptional co-activation. The detailed molecular mechanisms by
which PML-RARa co-activates HIF factors are still unknown.
Because PML-RARa indirectly interacts with HIF-a in cells and binds
to the promoters of bona fide HIF target genes (Martens et al, 2010;
Wang et al, 2010), it is possible that within specific DNA domains
rather than binding transcriptional co-repressors, PML-RARa
partakes to activating complexes that facilitate HIF-mediated tran-
scription. Moreover, as acute induction of PML-RARa increased
HIF-1a mRNA, it is also possible that in patients, HIF-1a is upregu-
lated upon PML-RARa expression, therefore adding an additional
level of cooperation between PML-RARa and HIF-1a.
The cooperation of PML-RARa with HIF-1a, and to a minor
extent HIF-2a, is relevant to APL pathogenesis by impacting on a
number of HIF-mediated functions, including spontaneous and
chemokine-dependent cell migration, and tumor neo-angiogenesis.
In addition, HIF-1a regulates self-renewal of APL leukemic blasts,
which is coherent with the role of HIF factors in regulating stem cell
maintenance in other hematopoietic contexts (Takubo et al, 2010;
Wang et al, 2011; Zhang et al, 2012; Rouault-Pierre et al, 2013).
However, in contrast to other hematological malignancies where
HIF-1a is found expressed predominantly in LICs (Wang et al, 2011;
Zhang et al, 2012), in APL, HIF-1a activation is triggered by a coop-
erative event with PML-RARa, whose expression is not confined to
LICs. Indeed, proof-of-principle experiments show that inhibition of
HIF-1a delays APL progression and prolong survival of leukemic
mice.
More remarkably, HIF-1a is also involved in regulating LICs
maintenance upon ATRA treatment. Specifically, ATRA increases
expression of HIF-1a in APL and other cell types (Meani et al,
2005), and HIF-1a inhibition exquisitely cooperates with ATRA
toward reducing APL LICs. In conclusion, our studies demonstrate
that HIF factors are important regulators of APL pathogenesis and
response to therapy.
Materials and Methods
Cell culture and reagents
NB4, U937-PR9 and U937-MT cells (Grignani et al, 1998) (kindly
provided by S. Minucci) and mouse APL cells were maintained in
RPMI 1640; HEK-293 and Phoenix-ECO in DMEM and HEK-293T in
IMDM media supplemented with 10% FBS and antibiotics (Lonza).
Primary mouse embryonic fibroblasts (MEFs) from wild-type and
Pml
/ embryos were prepared as previously described (Bernardi
et al, 2004). All cell lines were maintained at 37°C in humidified
atmosphere containing 5% CO2.
EZN-3088 (control LNA-ON for HIF-1a) and EZN-2968 (LNA-ON
for HIF-1a) (Greenberger et al, 2008) were provided by Belrose
Pharma Inc. and used in accordance with the manufacturer’s
instructions; ATRA, CoCl2 and Zn were purchased from Sigma;
ATRA pellets were from Innovative Research of America. All cyto-
kines were from Peprotech.
Lentiviral vectors
GIPZ HIF-1a and HIF-2a shRNA or control shRNA plasmids were
from Open Biosystems. Lentiviral vectors were obtained by HEK-
293T transfection with calcium phosphate and subsequent concen-
tration as previously described (Follenzi et al, 2000). HEK-293 and
NB4 cells were transduced by spinoculation and sorted for GFP
expression at least 2 weeks post-infection.
Immunoprecipitation and immunoblot
When indicated, NB4 cells (shCTRL or shHIFs) were treated for
24 h with 100 lM CoCl2 before lysis. For Western blot, proteins
were extracted with RIPA buffer (Sigma) supplemented with prote-
ase inhibitor cocktail (Roche); for luciferase assays, cells were lyzed
in passive lysis buffer (Promega); for co-immunoprecipitation
experiments, cells were lyzed after mild cross-linking with 0.4%
EMBO Molecular Medicine Vol 6 |N o5 | 2014 ª 2014 The Authors
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645formaldehyde (7 min at RT) in CO-IP buffer (10 mM NaCl, 10 mM
Tris–HCl pH 7.5, 5 mM MgCl2, 0.5% CHAPS) supplemented with
protease and phosphatase inhibitors (Pierce) and then briefly
sonicated to extract nuclear proteins. Total lysates were immuno-
precipitated with an antibody against PML (PG-M3; Santa Cruz).
Cell extracts and immunoprecipitates were resolved by SDS–
PAGE 7.5–10% and transferred to a PVDF membrane (Biorad). Non-
specific binding was blocked in 5% non-fat milk for 1 h at RT and
blotted with the following antibodies: rabbit polyclonal HIF-1a
(Cayman), rabbit polyclonal PML (Santa Cruz) and rabbit polyclonal
PML (Novus). Mouse b-actin (Sigma) was used as internal loading
control.
In vitro binding assays
Histidine-tagged human HIF-1a full-length protein (His-HIF-1a) was
purchased from Abcam. GST-tagged HIF-2a full-length protein
(GST-HIF-2a) was purchased from Abnova. Biotin-labeled PML-
RARa protein was generated in reticulocyte lysates using the TNT
T7 coupled transcription/translation system (Promega). 30 lLo fin
vitro-translated biotin-labeled PML-RARa was mixed with 5 lgo f
His or His-HIF-1a, GST or GST-HIF-2a in a final volume of 1 mL of
binding buffer (10 mM NaCl, 10 mM Tris–HCl pH 7.5, 5 mM MgCl2,
0.5% CHAPS and 5 mM imidazole for HIF-1a) and incubated O/N
at 4°C followed by the addition of 40 ll of HIS-Select Nichel Affinity
Gel (Sigma) or glutathione–Sepharose 4B beads (GE Healthcare) and
a further incubation at 4°C for 2 h. After washing, beads were
analyzed by SDS–PAGE. His and GST proteins were kindly provided
by V. M. Neguembor.
The following antibodies were used: Streptavidin-HRP (Sigma),
mouse monoclonal GST (Sigma) and mouse monoclonal HIF-1a (BD
Biosciences).
Luciferase assays
Cells were plated in 24-well plates (Costar) and transfected by Lipo-
fectamine 2000 (Invitrogen) with a reporter plasmid expressing the
luciferase gene under the control of a hypoxia responsive element
(HRE)-containing promoter (kind gift of C. Simon). Plasmids
containing PML, RARa, PML-RARa, NPM-RARa, PLZF-RARa and
AML1-ETO or plasmids containing stable forms of HIF-1a and HIF-
2a, or wild-type HIF-1a for experiments in MEFs (kind gifts of
Figure 3. HIF-1a inhibition impairs APL progression in a xenograft model.
A Real-time PCR analysis of VEGF, HIF-1a and HIF-2a (the number indicates HIF-2a expression relative to VEGF) in NB4 cells.
B Immunoblot of HIF-1a in NB4 cells transduced with lentiviral vectors carrying control (shCTRL) or HIF-1a-directed shRNA (shHIF-1a) and treated with CoCl2.
C Real-time PCR analysis of HIF-1a, VEGF and CXCR4 in shHIF-1a NB4 cells relative to shCTRL cells.
D Spontaneous migration of shCTRL or shHIF-1a NB4 cells. Data are expressed as mean values  s.e.m of triplicates from one representative experiment out of three
with similar results.
E Total numbers of human CD13
+ shCTRL or shHIF-1a NB4 cells localizing to the BM of Rag2
/cc
/ mice 16 h after tail vein injection (over 2.5 × 10
6 events; n = 10,
from two independent experiments).
FC D 31 immunostaining of BM colonized by shCTRL or shHIF-1a NB4 cells. Graph on the left shows average number of microvessels per field (40×). Pictures on the
right show representative images (arrows indicate microvessels).
G Kaplan–Meier survival curve of Rag2
/cc
/ mice injected with shCTRL or shHIF-1a NB4 cells (n = 9).
H Colony-forming assay upon serial re-plating of shCTRL or shHIF-1a NB4 cells. Data represent the number of colonies per field (10×). Upper panels: Representative
pictures of colonies formed by shCTRL or shHIF-1a NB4 cells in methylcellulose.
I Real-time PCR analysis of HIF-1a in NB4 cells 24 h after transfection with EZN-2968 relative to cells transfected with EZN-3088.
J Spontaneous migration of NB4 cells 24 h after transfection with EZN-3088 or EZN-2968.
K Colony-forming assay of EZN-3088 or EZN-2968-transfected NB4 cells. For the first plating, cells were seeded 24 h after transfection.
L Kaplan–Meier survival curve of Rag2
/cc
/ mice injected with EZN-3088 and EZN-2968-transfected NB4 cells 24 h after transfection (n = 6 for EZN-3088 group
and n = 7 for EZN-2968 group).
Data information: Results from migration and colony-forming assays are expressed as mean values  s.e.m of triplicates from one representative experiment. All
experiments were repeated at least twice.
Source data are available for this figure.
◂
Figure 4. HIF-1a inhibition synergizes with ATRA toward LICs eradication.
A Real-time PCR analysis of HIF-1a in NB4 cells treated with 1 lM ATRA for the indicated times relative to untreated cells.
B Colony-forming assay of NB4 shCTRL or shHIF-1a cells pre-treated for 24 h with 1 lM ATRA and plated in methylcellulose after drug washout. Data represent
number of colonies per field (10×).
C Real-time PCR analysis of HIF-1a, VEGF and GLUT1 in mouse leukemic cells 24 h after transfection with EZN-2968 relative to cells transfected with EZN-3088.
D Spontaneous and SDF-1-induced migration of mouse leukemic cells 24 h after transfection with EZN-3088 or EZN-2968.
E Colony-forming assay of mouse leukemic cells 24 h after transfection with EZN-3088 or EZN-2968.
F Peripheral white blood cell counts of 129Sv mice injected with mouse APL blasts 24 h after transfection with EZN-3088 or EZN-2968. Blood was collected at day 21
(n = 6).
G Kaplan–Meier survival curve of 129Sv mice injected with mouse APL blasts 24 h after transfection with the corresponding LNA-ON (n = 7 for EZN-3088 and n = 8 for
EZN-2968).
H Kaplan–Meier survival curve of secondary recipient mice injected with BM cells from donor mice injected with APL blasts transfected with EZN-3088 or EZN-2968
and treated for 4 days with ATRA at day 21 post-leukemia challenge (n = 8 for EZN-3088 and EZN-2968 ATRA; n = 7 for EZN-3088 ATRA and EZN-2968).
I PML-RARa DNA real-time PCR analysis of BM cells extracted from donor leukemic mice injected with APL blasts transfected with EZN-3088 or EZN-2968 and treated
for 4 days with ATRA at day 21 post-leukemia challenge (n = 3). Data are presented as percentage of ATRA-treated over reciprocal untreated (NT) mice.
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646C. Simon) were transfected where indicated. HEK-293 cells were
treated for 8 h with 300 lM CoCl2. Renilla-expressing plasmid
was co-transfected for transfection normalization. Dual-Luciferase
Reporter Assay System (Promega) was used to measure firefly and
Renilla luciferase activities and their ratio calculated in a GloMax
luminometer (Promega).
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647Real-time PCR
RNA was isolated with the RNeasy mini kit (Qiagen). cDNA was
obtained by retro-transcription of 1 lg total RNA using Advantage
RT for PCR kit (Clontech) and analyzed by real-time PCR in 7900
Fast Real-Time PCR System (Applied Biosystem).
All probes for TaqMan assays were purchased from Applied
Biosystem. 18S was used as internal control. The relative expression
of different cDNAs was calculated using the 2DDCt method with
respect to control conditions, except for the analysis of VEGF and
HIF factors in NB4 cells where data were expressed using the 2DCt
method relative to 18S expression. All data represent mean values
of at least two independent experiments.
For PML-RARa DNA real-time PCR, DNA was extracted using
QIAamp DNA Micro kit (Qiagen) and quantified as previously
described (Nasr et al, 2008). 18S was used as internal control.
Methylcellulose colony-forming assays
For human cell lines, 5 × 10
3 cells were resuspended in Human
Methylcellulose Base Media (R&D) and plated in 35-mm culture dishes.
Cells were allowed to grow for 7–10 days and then colonies were
pooled, counted, and 5 × 10
3 cells were re-seeded for re-plating experi-
ments. When indicated Zn (100 lM) was added to the methylcellulose
medium. In pre-treatment experiments (Fig 4B), NB4 cells were treated
in liquid medium with ATRA (1 lM) for 24 h and plated in methylcel-
lulose after drugs washout. In CFU-L experiments of BM cells from
leukemic mice, 3 × 10
4 cells were seeded in MethoCult GF Medium
(STEMCELL Technologies) 24 h after transfection with EZN-3088 and
EZN-2968, and colonies were counted 7–10 days after plating.
Migration assays
For human cell lines, 1 × 10
6 cells were seeded in the upper cham-
ber of a transwell 6.5-mm diameter and 5-lM pore (Costar). Cells in
the lower chamber were counted by flow cytometer as number of
cells acquired per minute (LSR II Beckton Dickinson) 16 h after
seeding for NB4 cells and 2.5 h after seeding for U937-PR9 and
U937-MT cells. For migration experiments of BM leukemic cells
1.25 × 10
5 mouse leukemia cells were seeded 24 h after electropora-
tion and migration was assessed after 4 h.
Animal models
Rag2
/cc
/ immunocompromised mice were maintained in path-
ogen-free animal facility and treated in accordance with European
Union guidelines. All animal protocols were approved by the Institu-
tional Animal Care and Use Commitee (IACUC).
For homing experiments, mice were injected intravenously (i.v.)
with 5 × 10
6 NB4 cells (shCTRL or shHIF-1a) and euthanized after
16 h. BM samples were stained with anti-human CD13 antibody.
For survival experiments, mice were challenged i.v. with 7 × 10
5
NB4 cells (shCTRL or shHIFs) and sacrificed when terminally sick.
Transduction of Lin- BM cells from 129Sv mice with a modified
retroviral vector (pBABE backbone with DNGFR as a reporter)
expressing PML-RARa was performed as previously described (Min-
ucci et al, 2002). DNGFR-sorted cells (1 × 10
6) were inoculated i.v.
into lethally irradiated syngeneic mice. Mice were monitored period-
ically for clinical signs of disease and leukocytosis. When terminally
sick, animals were sacrificed and 1 × 10
6 leukemic BM cells were
inoculated into syngeneic recipients.
Mouse APL cells were transfected ex vivo with EZN-2968 and
EZN-3088 in an AmaxaTM 4D-NucleofectorTM System (Lonza) and
transplanted into syngeneic mice 24 h after transfection. 1 × 10
6
live cells per recipient mouse were transplanted for the experiments
in Fig 4F and G. For the experiments of Fig 4H, 5 × 10
5 cells trans-
fected with EZN-2968 or EZN-3088 were transplanted in 4 mice/
cohort, and mice were treated with ATRA for 4 consecutive days at
day 21 after leukemia challenge, when control animals showed
leukemia involvement in BM. Second transplantation was
performed with 1 × 10
6 cells. ATRA was administered by subcuta-
neous implantation of 2 release pellets (5 mg each).
Statistics
Two-sided t-tests were used to validate the significance of the data
analyzed and considered statistically significant when P < 0.05. For
survival experiments, Kaplan–Meier curves were analyzed with the
Mantel–Cox test.
mRNA expression data
We used the publicly available datasets GSE1729 (Gutierrez et al,
2005), GSE1159 (Valk et al, 2004) and GSE19556 (Theilgaard-
Monch et al, 2005) from the NIH Gene Expression Omnibus reposi-
tory to select mRNA expression data of APL BM samples (n = 25)
and normal promyelocytes (n = 3). The experimental platform was
Affymetrix GeneChip Human Genome HG-U133A for all the
samples. Raw data (retrieved as * CEL files) were pre-processed
using the GCRMA library (Wu & Irizarry, 2004) of the Bioconductor
project in the R environment.
To compare the expression levels of HIF-1a and HIF-2a (EPAS1),
we retrieved CD34
+ (n = 5) and APL (n = 14) samples from the
publicly available dataset GSE12662 (Payton et al 2009), containing
data acquired by means of the Affymetrix HG-U133 Plus 2.0 Array.
Data mining
Hypoxia related signatures were retrieved from the collection of
curated gene sets (c2) of the Molecular Signatures Database
(MSigDB). A gene set enrichment analysis (GSEA) (Subramanian
et al, 2005) was performed either using these publicly available gene
sets or applying an ad hoc list of direct HIF-1a targets. A t-statistic
metric was applied to establish the gene ranking, and significance
was provided both in terms of nominal P-value and as FDR Q-value
to take into account the adjustment for multiple hypothesis testing.
Supplementary Information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
Hypoxia-inducible transcription factors (HIF) have long been involved
in regulating tumor progression in a variety of solid tumors. More
recently, emerging literature is beginning to implicate HIF factors in
leukemogenesis. In acute myeloid leukemia, HIF-1a has been found
overexpressed in a sub-group of cancer cells with leukemia propagat-
ing capacity and was shown to regulate leukemia stem cell mainte-
nance. However, a specific functional interaction of HIF-1a with
oncogenic fusion proteins causative of specific leukemia sub-types has
not yet been investigated.
Results
We have studied the role of HIF-1a in acute promyelocytic leukemia
(APL), a sub-type of acute myeloid leukemia characterized by expres-
sion of the fusion protein PML-RARa. We found that although acting
predominantly as a transcriptional repressor, PML-RARa functionally
cooperates with HIF-1a and activates the expression of a number of
HIF-target genes, which then regulate leukemia progression at multiple
levels. As a consequence, inhibition of HIF-1a blunts leukemia progres-
sion, and also exquisitely cooperates with retinoic acid in eradicating
leukemia-initiating cells.
Impact
The impact of our study is twofold: on one hand, we provide molecu-
lar insights into the complex function of the PML-RARa oncoprotein,
by defining a new important function of PML-RARa as a HIF-1a-tran-
scriptional co-activator. On the other hand, our work places HIF factors
as important regulators of the pathogenesis and response to therapy of
acute promyelocytic leukemia, and prompt further investigation into
the role of HIF-1a factors in other types of leukemia.
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